株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

治療ワクチンの世界市場:成長率・市場動向・市場予測

Global Therapeutic Vaccines Market - Growth, Trends & Forecasts (2017 - 2022)

発行 Mordor Intelligence LLP 商品コード 391468
出版日 ページ情報 英文 211 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.78円で換算しております。
Back to Top
治療ワクチンの世界市場:成長率・市場動向・市場予測 Global Therapeutic Vaccines Market - Growth, Trends & Forecasts (2017 - 2022)
出版日: 2016年12月15日 ページ情報: 英文 211 Pages
概要

当レポートでは、世界の治療ワクチンの市場を調査し、市場の定義と概要、市場への影響因子および市場機会の分析、ワクチン区分・詳細製品・地域・主要国別の動向、競合環境と主要企業のプロファイル、将来の展望などをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場概要・産業動向

  • 現在の市場シナリオ
  • ポーターのファイブフォース分析

第6章 市場成長推進因子・阻害因子・市場機会・課題

  • 成長推進因子
  • 成長阻害因子
  • 市場機会
  • 市場課題

第7章 市場区分

  • タイプ別
    • 自己免疫疾患ワクチン
    • 神経疾患ワクチン
    • 癌ワクチン
    • 感染症ワクチン
  • 地域別
    • 北米
      • 米国
      • カナダ
      • メキシコ
    • 欧州
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スぺイン
      • スカンジナビア諸国
      • ベネルクス諸国
      • その他
    • アジア太平洋
      • 日本
      • 中国
      • インド
      • 韓国
      • オーストラリア&ニュージーランド
      • その他
    • 中東・アフリカ
      • GCC諸国
      • 南アフリカ
      • その他
    • 南米
      • ブラジル
      • アルゼンチン
      • その他

第8章 競合環境

  • M&A分析
  • 協力・提携
  • 新製品の投入

第9章 主要ベンダーの分析

  • Agenus Inc
  • Bavarian Nordic
  • Celtic Pharma
  • Cytos Biotechnology
  • Dendreon Corp
  • GlaxoSmithKline
  • Pfizer
  • Merck Serono
  • Novartis
  • Transgene

第10章 将来の展望

目次

The global therapeutic vaccines market valued at USD 11 billion in 2016 and is projected to reach USD 51 billion by 2022, at a CAGR of 29% during the forecast period. The increasing prevalence of chronic diseases, such as cancer and HIV/AIDS are fuelling the market growth.

Market Dynamics

The favorable funding for R&D, increasing investments by companies, and rise in the prevalence of chronic diseases are some of the factors that are propelling the growth of the market. However, high costs of the vaccines and stringent regulatory guidelines are turning out to be restraints for this market.

Market Segmentation

The global therapeutic vaccines market has been segmented by type and geography.

Type -

  • Auto Immune Diseases Vaccines
  • Neurological Disease Vaccines
  • Cancer Vaccines
  • Infectious Diseases Vaccines

The cancer vaccines sub-segment contributes the highest share.

Geography -

  • North America
  • Europe
  • Asia-Pacific
  • The Middle East and Africa
  • South America

North America has the largest market size, followed by Europe. Asia-Pacific is an emerging market for vaccines, owing to the rising population and large investments in the field of research and development.

Numerous players in this market are trying to expand their product portfolio in order to top the global market. Few companies have adopted product innovation and new product launches as their key business strategies to ensure their dominance in the market.

The major players in the therapeutic vaccines market are:

  • Agenus Inc.
  • Bavarian Nordic
  • Celtic Pharma
  • Cytos Biotechnology
  • Dendreon Corp
  • GlaxoSmithKline Plc
  • Pfizer Inc
  • Merck Serono
  • Novartis
  • Transgene S.A
  • Sanofi Pasteur
  • Others

Key Deliverables In The Study

  • Market analysis for the global therapeutic vaccines market, with region specific assessments and competition analysis.
  • Market definition along with the identification of key drivers, restraints, opportunities and challenges.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
  • Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.
  • Identification and analysis of the macro and micro factors that affect the global therapeutic vaccines market.
  • Insights of the market in the regions that have the highest potential for growth and also to identify the markets that are still untapped

Table of Contents

1. Introduction

  • 1.1. Study Deliverables
  • 1.2. Market Definition
  • 1.3. General Study Assumptions
  • 1.4. Report Description

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Analysis Methodology
  • 2.3. Study timeline
  • 2.4. Study Phases
    • 2.4.1. Secondary Research
    • 2.4.2. Discussion Guide
    • 2.4.3. Market Engineering & Econometric Model
    • 2.4.4. Expert Validation

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry trends

  • 5.1. Current Market Scenario
  • 5.2. Porter's Five Force Analysis
    • 5.2.1. Bargaining Power of Suppliers
    • 5.2.2. Bargaining Power of Consumers
    • 5.2.3. Threat to New Entrants
    • 5.2.4. Threat to Substitute Products and Services
    • 5.2.5. Competitive Rivalry Within the Industry

6. Market Drivers, Restraints, Opportunities, and Challenges Analysis

  • 6.1. Market Drivers
    • 6.1.1. Favorable Government Funding for Vaccine Development
    • 6.1.2. Increasing Investments by Companies
    • 6.1.3. Rising Prevalence of Disease
  • 6.2. Market Restraints
    • 6.2.1. High Cost of Vaccines
    • 6.2.2. Stringent Regulatory Guidelines
  • 6.3. Market Ppportunities
  • 6.4. Market Challenges

7. Market Segmentation

  • 7.1. By Type
    • 7.1.1. Auto Immune Disease Vaccines
    • 7.1.2. Neurological Disease Vaccines
      • 7.1.2.1. ACC-001
      • 7.1.2.2. CAD 106
      • 7.1.2.3. Parkinson's Vaccine
      • 7.1.2.4. Alzheimer's Vaccine
    • 7.1.3. Cancer Vaccines
      • 7.1.3.1. Multikine
      • 7.1.3.2. PR1 Peptide
      • 7.1.3.3. Trovax
      • 7.1.3.4. CYT004-MelQbG10
    • 7.1.4. Infectious Disease Vaccines
      • 7.1.4.1. Hepatitis C Vaccines
      • 7.1.4.2. HIV/AIDS Vaccine
      • 7.1.4.3. Other Infectious Disease Vaccines
  • 7.2. By Geography
    • 7.2.1. North America
      • 7.2.1.1. USA
      • 7.2.1.2. Canada
      • 7.2.1.3. Mexico
    • 7.2.2. Europe
      • 7.2.2.1. Germany
      • 7.2.2.2. France
      • 7.2.2.3. UK
      • 7.2.2.4. Italy
      • 7.2.2.5. Spain
      • 7.2.2.6. Scandinavia
      • 7.2.2.7. BENELUX
      • 7.2.2.8. Rest of Europe
    • 7.2.3. Asia-Pacific
      • 7.2.3.1. Japan
      • 7.2.3.2. China
      • 7.2.3.3. India
      • 7.2.3.4. South Korea
      • 7.2.3.5. Australia & New Zealand
      • 7.2.3.6. Rest of Asia-Pacific
    • 7.2.4. Middle East & Africa
      • 7.2.4.1. GCC
      • 7.2.4.2. South Africa
      • 7.2.4.3. Rest of Middle East & Africa
    • 7.2.5. South America
      • 7.2.5.1. Brazil
      • 7.2.5.2. Argentina
      • 7.2.5.3. Rest of South America

8. Competitive Landscape

  • 8.1. Mergers and Acquisitions Analysis
  • 8.2. Collaborationa and Partnerships
  • 8.3. New Product Launches

9. Key Vendor Analysis

  • 9.1. Agenus Inc
  • 9.2. Bavarian Nordic
  • 9.3. Celtic Pharma
  • 9.4. Cytos Biotechnology
  • 9.5. Dendreon Corp
  • 9.6. GlaxoSmithKline
  • 9.7. Pfizer
  • 9.8. Merck Serono
  • 9.9. Novartis
  • 9.10. Transgene

10. Future Outlook of the Market

Back to Top